Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for ...

Vivani Medical (Nasdaq:VANI) announced that it filed a Form 10 registration statement with the SEC to spin off its ...

Vivani’s CEO, Adam Mendelsohn, Ph.D., noted the importance of this milestone in establishing Cortigent as an independent entity dedicated to pioneering neurostimulation technology. Cortigent’s ...

Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it looks to prioritise its portfolio of weight loss drug implants. While ...

Cortigent is a precision neurostimulation technology that seeks to provide an artificial vision for blind people. Jonathan Adams has served as Cortigent's CEO since 2023 and will retain that ...

Company plans to spin off Cortigent, Inc., a division that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA ...

Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered paralysis due to stroke Spin-off will allow Vivani to focus on its ...

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion ...